Institute of Biomedical Research Corp. (MRES)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MRES steht fuer Institute of Biomedical Research Corp., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 42/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Institute of Biomedical Research Corp. (MRES) Gesundheitswesen & Pipeline-Uebersicht
Institute of Biomedical Research Corp., based in Montenegro, offers biomedical research, analytical services, and product development. The company focuses on regulatory compliance, environmental surveillance, and creating innovative healthcare solutions. With a global reach, including a Canadian office, it serves the biotechnology sector through diverse research and product offerings.
Investmentthese
Institute of Biomedical Research Corp. operates in a niche segment of the biotechnology industry, focusing on biomedical research, analytical services, and specialized product development. With a market capitalization of $0.01 billion and a negative P/E ratio of -26.31, the company's financial performance reflects challenges in achieving profitability, indicated by a profit margin of -588.7%. However, a gross margin of 38.4% suggests potential in its core operations. Growth catalysts include expanding its regulatory and environmental service offerings, as well as commercializing its range of biomedical products. Key risks involve achieving sustainable profitability and navigating regulatory hurdles in international markets.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.01 billion reflects its small size within the biotechnology sector.
- Negative P/E ratio of -26.31 indicates the company is currently not profitable.
- Profit margin of -588.7% highlights significant challenges in achieving profitability.
- Gross margin of 38.4% suggests potential in its core operations despite overall losses.
- Beta of 0.04 indicates low volatility relative to the market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diverse range of biomedical research and analytical services.
- Development and commercialization of specialized biomedical products.
- Expertise in regulatory compliance and environmental analysis.
- Established presence in Montenegro with international reach.
Schwaechen
- Low profitability and negative profit margins.
- Limited market capitalization and financial resources.
- Dependence on niche markets and specialized applications.
- OTC market listing may limit investor access and liquidity.
Katalysatoren
- Ongoing: Expansion of regulatory and environmental service offerings.
- Upcoming: Commercialization of new biomedical products in international markets.
- Ongoing: Development of new diagnostic methods and experimental treatments.
- Upcoming: Strategic partnerships with research institutions and healthcare providers.
Risiken
- Ongoing: Low profitability and negative profit margins.
- Potential: Limited market capitalization and financial resources.
- Ongoing: Dependence on niche markets and specialized applications.
- Potential: OTC market listing may limit investor access and liquidity.
- Potential: Intense competition in the biotechnology sector.
Wachstumschancen
- Expanding Regulatory and Environmental Services: Institute of Biomedical Research Corp. can capitalize on the growing demand for regulatory compliance and environmental services. By offering specialized services in regulatory certifications and environmental analysis, the company can attract clients seeking to navigate complex regulatory landscapes. The market for environmental services is projected to reach $1.2 trillion by 2027, presenting a significant growth opportunity.
- Commercializing Biomedical Products: The company has the potential to drive revenue growth by commercializing its range of biomedical products, including microbicidal agents, disinfectant products, and healthcare devices. Focusing on niche markets and specialized applications can help the company differentiate its products and capture market share. The global market for medical devices is expected to reach $600 billion by 2025.
- Developing New Diagnostic Methods: Investing in the development of new diagnostic methods and experimental medical treatments can position the company as an innovator in the biotechnology sector. By focusing on unmet medical needs and emerging technologies, the company can attract research funding and partnerships. The market for diagnostic testing is projected to reach $115 billion by 2028.
- Geographic Expansion: Expanding its geographic reach beyond Montenegro and Canada can open up new markets and revenue streams. Targeting regions with growing healthcare sectors and unmet medical needs can help the company diversify its operations and reduce its reliance on domestic markets. Emerging markets in Asia and Latin America offer significant growth potential.
- Strategic Partnerships: Forming strategic partnerships with other companies in the biotechnology sector can provide access to new technologies, markets, and resources. Collaborating with research institutions, pharmaceutical companies, and healthcare providers can accelerate product development and commercialization. Strategic alliances can also help the company expand its capabilities and enhance its competitive position.
Chancen
- Expanding regulatory and environmental service offerings.
- Commercializing biomedical products in new markets.
- Developing new diagnostic methods and experimental treatments.
- Forming strategic partnerships with other companies and institutions.
Risiken
- Intense competition in the biotechnology sector.
- Stringent regulatory requirements and compliance costs.
- Economic downturns and market volatility.
- Technological advancements and disruptive innovations.
Wettbewerbsvorteile
- Specialized Expertise: Deep expertise in biomedical research, regulatory compliance, and environmental analysis.
- Proprietary Technologies: Development and commercialization of unique biomedical products and technologies.
- Regulatory Certifications: Ability to provide regulatory certifications for new biomedical products.
- Established Presence: Long-standing presence in Montenegro with a growing international footprint.
Ueber MRES
Founded in 2010, Institute of Biomedical Research Corp. is a biotechnology company based in Podgorica, Montenegro, with a representative office in Montreal, Canada. The company provides a range of biomedical research and analytical services both domestically and internationally. Its core activities encompass regulatory control of industrial activities and products, scientific surveillance of the living environment, and research and development of biomedical products and technologies. The company also focuses on regulatory evaluation and certification of biomedical products, fundamental scientific research, and the development of new diagnostic methods and experimental medical treatments. Institute of Biomedical Research Corp. researches and develops new biomedical and food products, offering graduate research programs in biomedical and environmental fields. The company provides a variety of healthcare devices, including analog NMS, digital muscle stimulators, and ultrasound devices. It also develops and commercializes microbicidal agents, disinfectant products, and various specialized products like bandages for burns, insecticides, and microbicidal towels. Further, the company offers services such as quality control, regulatory consulting, healthcare solutions, environmental analysis, building decontamination, and environmental protection and management. It also provides regulatory certifications for new biomedical products. The company's innovations include Purilair, a device for sterilizing compressed air in medical instruments, colloidal silver products, electro medical devices, and BioStim INF, used for edema reduction and pain relief.
Was das Unternehmen tut
- Provides regulatory control of industrial activities and products.
- Conducts scientific surveillance of the living environment.
- Engages in research and development of biomedical products and technologies.
- Offers regulatory evaluation and certification of biomedical products.
- Conducts fundamental scientific research.
- Develops new diagnostic methods and experimental medical treatments.
- Researches and develops new biomedical and food products.
- Provides programs for graduate research studies in biomedical and environmental fields.
Geschaeftsmodell
- Provides biomedical research and analytical services to various industries.
- Develops and commercializes biomedical products and technologies.
- Offers regulatory evaluation and certification services for biomedical products.
- Generates revenue through the sale of healthcare devices and specialized products.
Branchenkontext
Institute of Biomedical Research Corp. operates within the global biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The company's focus on biomedical research, analytical services, and specialized product development positions it within a niche segment of the market. Key trends in the industry include the increasing demand for personalized medicine, the growing importance of regulatory compliance, and the rise of environmental concerns. Competitors include companies like BBIXF, CAAOF, CHOOF, CLYYF, and ELVAF, which operate in similar areas of biomedical research and product development.
Wichtige Kunden
- Industrial companies requiring regulatory control and compliance.
- Healthcare providers seeking advanced diagnostic methods and treatments.
- Research institutions and universities involved in biomedical research.
- Government agencies responsible for environmental surveillance and protection.
Finanzdaten
Chart & Info
Institute of Biomedical Research Corp. (MRES) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 8. Okt. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer MRES.
Kursziele
Wall-Street-Kurszielanalyse fuer MRES.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von MRES auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Drasko D. Pekovic
CEO
Drasko D. Pekovic serves as the CEO of Institute of Biomedical Research Corp. His background includes extensive experience in biomedical research and development, with a focus on regulatory compliance and environmental analysis. He has been instrumental in guiding the company's strategic direction and expanding its international presence. Dr. Pekovic holds advanced degrees in biomedical sciences and has published numerous research papers in peer-reviewed journals.
Erfolgsbilanz: Under Dr. Pekovic's leadership, Institute of Biomedical Research Corp. has expanded its range of biomedical research and analytical services, as well as developed and commercialized several specialized biomedical products. He has also overseen the company's efforts to obtain regulatory certifications and expand its geographic reach. Key milestones include establishing a representative office in Montreal, Canada, and securing partnerships with research institutions.
MRES OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Institute of Biomedical Research Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information and liquidity.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited liquidity and trading volume.
- Lack of regulatory oversight and financial disclosure.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited access to capital and financing options.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive position.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any red flags or warning signs in the company's history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established presence in Montenegro with international reach.
- Development and commercialization of specialized biomedical products.
- Expertise in regulatory compliance and environmental analysis.
- CEO with extensive experience in biomedical research and development.
Was Anleger ueber Institute of Biomedical Research Corp. (MRES) wissen wollen
What are the key factors to evaluate for MRES?
Institute of Biomedical Research Corp. (MRES) currently holds an AI score of 42/100, indicating low score. Key strength: Diverse range of biomedical research and analytical services.. Primary risk to monitor: Ongoing: Low profitability and negative profit margins.. This is not financial advice.
How frequently does MRES data refresh on this page?
MRES prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MRES's recent stock price performance?
Recent price movement in Institute of Biomedical Research Corp. (MRES) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse range of biomedical research and analytical services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MRES overvalued or undervalued right now?
Determining whether Institute of Biomedical Research Corp. (MRES) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MRES?
Before investing in Institute of Biomedical Research Corp. (MRES), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MRES to a portfolio?
Potential reasons to consider Institute of Biomedical Research Corp. (MRES) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diverse range of biomedical research and analytical services.. Additionally: Development and commercialization of specialized biomedical products.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of MRES?
Yes, most major brokerages offer fractional shares of Institute of Biomedical Research Corp. (MRES) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track MRES's earnings and financial reports?
Institute of Biomedical Research Corp. (MRES) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for MRES earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited financial information available for Institute of Biomedical Research Corp.
- OTC market listing increases investment risk.